WYETH-AYERST NORMIFLO LMWH APPROVAL "LIKELY" IN 1994/1995
WYETH-AYERST NORMIFLO LMWH APPROVAL "LIKELY" IN 1994/1995, Wyeth-Ayerst Research President Robert Levy, MD, forecast in a presentation at the Bear Stearns Seventh Annual Health Care Conference in New York City Sept. 21. Normiflo low molecular weight heparin for the once-a-day treatment of coronary artery disease "has been at FDA for two years now," Levy told Bear Stearns conference attendees. "We feel we have answered all of the FDA's questions and we hope for approval within the next six months, hopefully by the end of the year."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth